Layn(002166)2025-04-25 13:00Financial Performance - The company's operating revenue for Q1 2025 was ¥444,292,336.62, representing a 30.21% increase compared to ¥341,215,308.03 in the same period last year[3]. - The net profit attributable to shareholders was ¥30,794,889.80, up 14.95% from ¥26,790,064.13 year-on-year[3]. - The net cash flow from operating activities surged to ¥182,936,113.99, a remarkable increase of 1,059.54% compared to ¥15,776,635.33 in Q1 2024[3]. - The company achieved a consolidated revenue of RMB 444.29 million, representing a year-on-year growth of 30.21%[15]. - The net profit attributable to shareholders was RMB 30.79 million, reflecting a year-on-year increase of 14.95%[16]. - The total operating revenue for the current period reached ¥444,292,336.62, an increase from ¥341,215,308.03 in the previous period, representing a growth of approximately 30.3%[24]. - The net profit for the current period was ¥32,670,555.04, compared to ¥27,884,546.77 in the previous period, reflecting an increase of approximately 17.5%[24]. - Total comprehensive income for the period reached CNY 32,781,800.18, an increase from CNY 29,338,961.00 in the previous period[25]. Cash Flow and Liquidity - The net cash flow from investing activities improved by 24.54%, with a net outflow of ¥53,184,747.45 compared to ¥70,477,251.46 in the previous year[12]. - The company’s cash and cash equivalents increased significantly by 158,723,372.71, driven by reduced payments for raw materials and lower project expenditures[12]. - The company's cash and cash equivalents increased significantly to ¥324,448,748.77 from ¥165,063,469.93, showing a growth of about 96.5%[22]. - Cash inflow from financing activities amounted to CNY 296,988,408.50, an increase from CNY 211,606,225.00 in the prior period[27]. - Cash outflow from investing activities was CNY 53,324,549.53, down from CNY 70,478,201.46 in the previous period[27]. - Operating cash inflows totaled CNY 604,090,293.78, a decrease from CNY 665,699,925.37 in the previous period[26]. - Total cash outflows from operating activities were CNY 421,154,179.79, down from CNY 649,923,290.04 in the prior period[27]. Assets and Liabilities - The company's total assets at the end of Q1 2025 were ¥5,040,659,836.76, reflecting a slight increase of 0.44% from ¥5,018,729,917.67 at the end of the previous year[3]. - The total liabilities increased to ¥1,852,339,156.29 from ¥1,817,808,526.60, which is an increase of approximately 1.9%[23]. - The total equity attributable to the parent company was ¥3,109,482,311.84, down from ¥3,123,958,687.68, representing a decrease of about 0.5%[23]. Operating Costs and Expenses - The company reported a significant increase in operating costs, which rose by 37.31% to ¥346,461,298.63 due to higher sales volume[10]. - The financial expenses increased by 132.43% to ¥8,041,772.43, primarily due to reduced exchange gains and increased interest expenses[10]. - The total operating costs amounted to ¥402,259,540.14, up from ¥297,588,999.84, indicating a rise of about 35.2%[24]. - The company's R&D expenses for the current period were ¥11,524,403.03, compared to ¥9,659,639.15 in the previous period, reflecting an increase of about 19.3%[24]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 52,109, with the largest shareholder holding 36.59% of the shares[13]. - As of January 24, 2025, the company completed a share repurchase of 15,275,701 shares, accounting for 2.06% of the total share capital, with a total transaction amount of RMB 104.99 million[17]. Strategic Focus and Development - The company is focusing on optimizing its overseas supply chain and advancing the commercialization of synthetic biotechnology[15]. - The subsidiary Hemprise, LLC has been renamed to BIOVIVO SCIENCE, LLC, aiming to enhance competitiveness in the global market[18]. - The company plans to upgrade its Indiana plant to become a high-standard comprehensive production base for plant extracts[18]. - The company emphasizes cost control and differentiation to ensure steady business growth in the natural health ingredients sector[16]. - The company is actively exploring new fields, technologies, and models to strengthen its market position[16]. - The company’s strategic focus for 2025 is "thinking and innovating" to navigate global economic uncertainties[15].